Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant pembrolizumab in stage IIB-C melanoma
Melanoma · PERIO-MEL-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This claim asks whether adding pembrolizumab after surgery helps patients with stage IIB or IIC melanoma go longer without the cancer coming back. The corpus contains one large, well-run, blinded randomised trial, KEYNOTE-716, reported in several papers [7][11][16][17][15], which compared pembrolizumab against a placebo in 976 such patients. Every report of that trial shows fewer recurrences with pembrolizumab, and the measure the claim names, recurrence-free survival, was the trial's own main outcome rather than a stand-in. The panel judged this a direct, internally consistent match to the claim. It held back from full certainty mainly because all the direct evidence comes from that single trial and because longer-term survival data are not yet mature.
The corpus demonstrates a consistent reduction in recurrence with adjuvant pembrolizumab versus placebo in resected stage IIB/IIC melanoma across every reported data cut of KEYNOTE-716: a recurrence hazard ratio of 0.64 at earlier analyses [16][17][15] and 0.62 at the final analysis [7][11], with 36-month recurrence-free survival of 76.2% versus 63.4% [7][11] and 24-month recurrence-free survival of 81.2% versus 72.8% [16]. The effect holds across stage IIB and IIC subgroups [11] and across histopathologic subgroups [15], and recurrence-free survival was the trial's prespecified primary endpoint [11][17]. A quality-of-life report from the same trial corroborates the recurrence-free survival improvement [9]. Class and setting plausibility is reinforced by stage III pembrolizumab versus placebo (HR 0.57) [3] and a single-arm neoadjuvant-adjuvant stage IIB/C cohort with 2-year recurrence-free survival of 84% [22], though neither is a placebo-controlled test in the exact population. The contested point: The division is not over whether the recurrence-free survival effect is real but over how much weight one trial can carry: all directly confirmatory papers [7][9][11][15][16][17] are KEYNOTE-716, so there is no independent replication in the corpus. A secondary point is that no paper demonstrates a statistically significant overall-survival benefit; outcomes are recurrence-free and distant metastasis-free survival with medians not reached [7][11][16][17].
All 33 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All directly confirmatory evidence ([7][9][11][15][16][17]) derives from a single trial, KEYNOTE-716, reported repeatedly. There is no independent replication, so evidential independence is minimal and the verdict rests entirely on one study.
No included paper demonstrates a statistically significant overall-survival benefit; outcomes are RFS and DMFS with medians not reached. The RFS benefit is real but longer-term mortality impact is unestablished in this corpus.
Where it remains uncertain. Every confirmatory paper is the same trial [7][9][11][15][16][17], so there is no independent replication, and no corpus paper shows a significant overall-survival benefit [7][11].
Aleatory
Recurrence-free and distant metastasis-free survival medians were not reached in either arm [7][11][16][17], so later-occurring events could still shift absolute estimates.
Epistemic
All directly confirmatory evidence is a single trial, KEYNOTE-716 [7][9][11][15][16][17]; the corpus contains no second placebo-controlled trial in this population.
Inferential
Plausibility leans on stage III data [3] and a single-arm n=63 cohort [22], which are not placebo-controlled tests in resected stage IIB-C and so can only be read as class-consistent, not confirmatory.
The load-bearing papers from a corpus of 33, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Final analysis confirming durable RFS separation at 36 months.
“The median RFS was not reached in either treatment group, and the estimated 36-month RFS was 76.2% for pembrolizumab and 63.4% for placebo (HR, 0.62 [95% CI, 0.49 to 0.79]).”
Panel auditInternal validity: high · scope of inference: Resected stage IIB and IIC cutaneous melanoma with negative sentinel node.Key limitations: RFS was secondary focus here (DMFS final analysis) · no formal hypothesis testing on this cut
Demonstrates benefit holds in both the IIB and IIC subgroups named in the claim.
“Similar results were observed with RFS (stage IIB HR, 0.58 [95% CI, 0.43-0.79]; stage IIC HR, 0.65 [95% CI, 0.45-0.94]).”
Panel auditInternal validity: high · scope of inference: Resected stage IIB and IIC cutaneous melanoma, negative sentinel node.Key limitations: conference abstract · no formal hypothesis testing at this cut
Confirms overall RFS HR and consistency across histopathologic subgroups.
“At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84)”
Panel auditInternal validity: high · scope of inference: Resected stage IIB/IIC melanoma across histopathologic subtypes.Key limitations: subgroup analyses post hoc · some subgroup CIs cross 1
RFS benefit is clear in stage III disease, but this abstract does not report the stage IIB-C population the claim asks about, so direction for that population is not determinable here.
Panel auditInternal validity: high · scope of inference: Resected high-risk stage III melanoma.Key limitations: wrong stage (III, not IIB-C) · population not covered by claim
4 of 33 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A robust, internally consistent pivotal RCT carries the claim at its primary endpoint; confidence is held just below the top of the band by single-trial dependence and immature overall survival.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent replication in stage IIB-C. The entire direct case rests on one trial [7][11][17], leaving the effect's reproducibility untested within this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independent placebo- or observation-controlled randomised trial of adjuvant anti-PD-1 in resected stage IIB-C melanoma reporting recurrence-free survival.
Open question: Does the recurrence-free survival benefit of adjuvant pembrolizumab in stage IIB-C melanoma translate into a statistically significant overall-survival benefit? Why it is still open: Every corpus report of KEYNOTE-716 shows recurrence-free and distant metastasis-free survival with medians not reached and no significant overall-survival result [7][11][16][17].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19